

***Remarks***

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 1-7, 9-33, 36-66 and 71-155 are pending in the application, with claims 1, 74, 76, 78, 82, 148, 151 and 154 being the independent claims. Claims 1, 46, 59, 76 and 78 are sought to be amended, and new claims 82-155 are sought to be added.


The claims have been amended to revise dependency and/or for grammatical purposes. Support for new claims 82-155 can be found throughout the specification and in the claims as originally filed. In particular, support for claims 82, 148, 151 and 154 can be found, for example, in the specification at page 7, line 23 to page 11, line 4. Support for claims 83-147 can be found in claims 2-73 as originally filed. Support for claim 149 can be found in original claim 75. Support for claims 150, 153 and 155 can be found, for example, in the specification at page 27, lines 11-13 and in claims 20, 35 and 68 as filed. Support for claim 152 can be found in original claim 77. These changes are believed to introduce no new matter, and their entry is respectfully requested.

***Conclusion***

Applicants respectfully request that the Examiner reconsider all presently outstanding objections and rejections and that they be withdrawn. Prompt and favorable consideration of this Supplemental Amendment is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Peter A. Jackman  
Attorney for Applicants  
Registration No. 45,986

Date: Sept. 4, 2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

SKGF\_DC1:52410.1

B

**Version with Markings to Show Changes Made**

The following claims 1, 46, 59, 76 and 78 were substituted for the pending claims 1, 46, 59, 76 and 78:

1. (Twice amended) A pharmaceutical composition, comprising:  
(a) a polypeptide comprising Ser (69) - Ser (208) of SEQ ID NO:2 in a concentration range of about 0.02 to about 40 mg/ml (w/v);  
(b) a buffer having a buffering capacity of about pH 5.0 to about pH 8.0 at a concentration range of about 5 mM to about 50 mM;  
(c) a pharmaceutically acceptable diluent to bring the composition to a designated volume; and  
(d) a preservative selected from the group consisting of m-cresol, chlorobutanol, and a mixture of methyl paraben and propyl paraben[; or a reaction product thereof].

46. (Once amended) The pharmaceutical composition of claim 44 [claim 40], wherein said etherified cellulose is methylcellulose, hydroxyethyl cellulose, hydroxy propyl cellulose, hydroxy propyl methylcellulose, or carboxymethyl cellulose.

59. (Once amended) The composition of claim 58, wherein said gel forming agent is (1) a vinyl polymer selected from the group consisting of polyacrylic acid, polymethacrylic acid, polyvinyl pyrrolidone polyvinyl alcohol, and salts and esters thereof; or (2) a polysaccharide selected from the group consisting of a cellulose derivative, a glycosaminoglycan, agar, pectin, alginic acid, dextran,  $\alpha$ -amylose, amylopectin, chitosan, and salts or esters thereof.

76. (Twice amended) A pharmaceutical composition comprising:  
(a) about 3.3 mg/ml of a polypeptide comprising Ser (69) - Ser (208) of SEQ ID NO:2;  
(b) 10 mM sodium citrate  
(c) 20 mM sodium chloride;  
(d) 1 mM EDTA  
(e) 2% w/v glycine;  
(f) 0.5% w/v sucrose; and  
(g) water; [and  
(h) pH about 6.2;  
or a reaction product thereof] wherein the composition is at a pH of about 6.2.

78. (Twice amended) A pharmaceutical composition comprising:  
SEQ ID NO:2; (a) about 1.0 mg/ml of a polypeptide comprising Ser (69) - Ser (208) of  
(b) 10 mM sodium citrate;  
(b) 0.46% hydroxyethylcellulose;  
(c) 7% sucrose;  
(d) 20 mM sodium citrate;  
(e) 20 mM sodium chloride; and  
(f) 1 mM EDTA; [and  
(g) pH about 6.2;  
or reaction products thereof] wherein the composition is at a pH of about 6.2.

Claims 82 to 155 were added.